SEARCH

SEARCH BY CITATION

References

  • Abrams SM, Degnan TJ & Vinciguerra V (1980): Marrow aplasia following topical application of chloramphenicol eye ointment. Arch Intern Med 140: 576577.
  • Aoki K & Tagawa Y (2002): A twenty-one year surveillance of adenoviral conjunctivitis in Sapporo, Japan. Int Ophthalmol Clin 42: 4954.
  • Besamusca FW & Bastiaensen LA (1986): Blood dyscrasias and topically applied chloramphenicol in ophthalmology. Doc Ophthalmol 64: 8795.
  • Block SL, Hedrick J, Tyler R, Smith A, Findlay R, Keegan E & Stroman DW (2000): Increasing bacterial resistance in pediatric acute conjunctivitis (1997–1998). Antimicrob Agents Chemother 44: 16501654.
  • Brennen C & Muder RR (1990): Conjunctivitis associated with methicillin resistant Staphylococcus aureus in a long-term-care facility. Am J Med 88: 1417.
  • Brown EM & Thomas P (2002): Fusidic acid resistance in Staphylococcus aureus isolates. Lancet 359: 803.
  • Buckley SA (1990): Survey of patients taking topical medication at their first presentation to eye care casualty. Br Med J 300: 14971498.
  • Buckley RJ, Kirkness CM, Kanski JJ, Ridgway AE, Tullo AB & Watson PG (1995): Safe in patients with no history of blood dyscrasia. Br Med J 311: 451.
  • Buznach N, Dagan R & Greenberg D (2005): Clinical and bacterial characteristics of acute bacterial conjunctivitis in children in the antibiotic resistance era. Pediatr Infect Dis J 24: 823828.
  • Cagle CD & Abshire RL (1981): Quantitative ocular bacteriology. Invest Ophth Vis Sci 20: 751757.
  • Carpenter G (1975): Chloramphenicol eye-drops and marrow aplasia. Lancet Aug 16: 326327.
  • Carr WD (1998): Comparison of Fucithalmic® (fusidic acid viscous eye drops 1%) and Chloromycetin Redidrops® (chloramphenicol eye drops 0.5%) in the treatment of acute bacterial conjunctivitis. J Clin Res 1: 403411.
  • Chaudhry NA, Flynn HW, Murray TG, Tabandeh H, Mello MJ & Miller D (1999): Emerging ciprofloxacin-resistant pseudomonas aeruginosa. Am J Ophhtalmol 128: 509510.
  • Cvenkel B & Globocnik M (1997): Conjunctival scrapings and impression cytology in chronic conjunctivitis. Correlation with microbiology. Eur J Ophthalmol 7: 1923.
  • Dannevig L, Straume B & Melby K (1992): Ophthalmia neonatorum in Northern Norway. II. Microbiology with emphasis on Chlamydia trachomatis. Acta Ophthalmol (Copenh) 70: 1925.
  • Dart JKG (1986): Eye disease at a community health centre. Br Med J 293: 14771480.
  • Dawson CR, Hanna L & Togni B (1972): Adenovirus type 8 infections in the United States. IV. Observations on the pathogenesis of lesions in severe eye disease. Arch Ophthalmol 87: 258268.
  • Dobie D & Gray J (2004): Fusidic acid resistance in Staph. Aureus. Arch Dis Child 89: 7477.
  • Doern GV, Brueggemann A, Holley HP & Rauch AM (1996): Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrobial Agents Chemotherapy 40: 12081213.
  • Doona M & Walsh JB (1995): Use of chloramphenicol as topical eye medication: time to cry halt? Br Med J 310: 12171218.
  • Doona M & Walsh JB (1998): Topical chloramphenicol is an outmoded treatment. Br Med J 316: 1903.
  • Ehlers N & Bek T (2004): Akut purulent conjunctivitis. In: HøvdingG (ed.) Oftalmologi. Nordisk lærebok og atlas. Bergen: Studia, 129132.
  • El-Zimaity D, Kearns AM, Dawson SJ, Price S & Harrison GA (2004): Survey, characterization and susceptibility to fusidic acid of Staphylococcus aureus in the Camarthen area. J Antimicrob Chemother 54: 441446.
  • Everitt H, Kumar S & Little P (2003): A qualitative study of patients' perceptions of acute infective conjunctivitis. Br J General Pract 53: 3641.
  • Everitt H & Little P (2002): How do GPs diagnose and manage acute infective conjunctivitis? A GP survey. Fam Pract 19: 658660.
  • Everitt HA, Little PS & Smith PW (2006): A randomised controlled trial of management strategies for acute infective conjunctivitis in general practice. Br Med J 333: 321324.
  • Fahmy JA, Møller S & Weiss Bentzon M (1975): Bacterial flora of the normal conjunctiva II. Methods of obtaining cultures. Acta Ophthalmol (Copenh) 53: 237253.
  • Fitch CP, Rapoza PA, Owens S, Murillo-Lopez F, Johnson RA, Quinn TC, Pepose JS & Taylor HR (1989): Epidemiology and diagnosis of acute conjunctivitis at an inner-city hospital. Ophthalmology 96: 12151220.
  • Franklin RM, Winkelstein JA & Seto DSY (1977): Conjunctivitis and keratoconjunctivitis associated with primary immunodeficiency diseases. Am J Ophthalmol 84: 563566.
  • Fraunfelder FT, Bagby GC & Kelly DJ (1982): Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol. Am J Ophthalmol 93: 356360.
  • Fraunfelder FT, Morgan RL & Yunis AA (1993): Blood dyscrasias and topical ophthalmic chloramphenicol. Am J Ophthalmol 115: 812813.
  • Friedlaender MH, Masi RJ, Osumoto M, Smolin G & Ammann AJ (1980): Ocular microbial flora in immunodeficient patients. Arch Ophthalmol 98: 289294.
  • Garibaldi RA, Brodine S & Matsumiya S (1981): Infections among patients in nursing homes. N Engl J Med 305: 731735.
  • Gigliotti F, Williams WT, Hayden FG & Hendley JO (1981): Etiology of acute conjunctivitis in children. J Pediatr 98: 531536.
  • Goldstein MH, Kowalski RP & Gordon YJ (1999): Emerging fluoroquinolone resistance in bacterial keratitis. Ophthalmology 106: 13131318.
  • Gritz DC, Scott TJ, Sedo SF, Cevallos AV, Margolis TP & Whitcher JP (1997): Ocular flora of patients with AIDS compared with those of HIV-negative patients. Cornea 16: 400405.
  • Hilton E, Adams AA, Uliss A, Lesser ML, Samuels S & Lowy FD (1983): Nosocomial bacterial eye infections in intensive-care units. Lancet 11: 13181320.
  • Hørven I (1993): Acute conjunctivitis. A comparison of fusidic acid viscous eye drops and chloramphenicol. Acta Ophthalmol (Copenh) 71: 165168.
  • Hørven I (1994): Bakteriell konjunktivitt [Bacterial conjunctivitis]. Tidsskr Nor Lægeforen 114: 661.
  • Høvding G (1981): The conjunctival and contact lens bacterial flora during lens wear. Acta Ophthalmol (Copenh) 59: 387401.
  • Høvding G (2004): Akutt bakteriell konjunktivitt [Acute bacterial conjunctivitis]. Tidsskr Nor Lægeforen 124: 15181520.
  • Høvding G & Bertelsen T (2004): Kontaktlinser. In: HøvdingG (ed.) Oftalmologi. Nordisk lærebok og atlas. Bergen: Studia, 103108.
  • Høvding G, Bratland SZ & Digranes A (1991): Rødt øye – praktisk veiledning i allmenn praksis. Oslo: Løvens Kemiske Fabrik.
  • Howden BP & Grayson ML (2006): Dumber and dumber – the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis 42: 394400.
  • Inoue Y (2002): Ocular infections in patients with atopic dermatitis. Int Ophthalmol Clin 42: 5569.
  • Isenberg SJ, Apt L, Yoshimori R, McCarty JW & Alvarez RN (1988): Source of the conjunctival bacterial flora at birth and implications for ophthalmia neonatorum prophylaxis. Am J Ophthalmol 106: 458462.
  • Jackson WB, Low DE, Dattani D, Whitsitt PF, Leeder RG & MacDougall R (2002): Treatment of acute bacterial conjunctivitis: 1% fusidic acid viscous drops vs. 0.3% tobramycin drops. Can J Ophthalmol 37: 228237.
  • Jett BD (2005): Host defence against ocular infection. In: TasmanM & JaegerEA (eds) Duane's clinical ophthalmology, vol. 2. Philadelphia: Lippincott, Williams & Wilkins, 120.
  • Kass MA, Gordon M, Morley RE, Meltzer DW & Goldberg JJ (1987): Compliance with topical timolol treatment. Am J Ophthalmol 103: 188193.
  • Kernt K, Martinez M, Bertin D, Stroman D, Cupp G, Martinez C, Tirado M & Guasch J (2005): A clinical comparison of two formulations of tobramyin 0.3% eyedrops in the treatment of acute bacterial conjunctivitis. Eur J Ophthalmol 15: 541549.
  • King S, Devi SP, Mindorff C, Patrick ML, Gold R & Ford-Jones EL (1988): Nosocomial pseudomonas aeruginosa conjunctivitis in a pediatric hospital. Infect Control Hosp Epidemiol 9: 7780.
  • Kowalski RP & Roat MI (2005): Normal flora of the human conjunctiva and eyelid. In: TasmanM & JaegerEA (eds) Duane's clinical ophthalmology, vol. 2. Philadelphia: Lippincott, Williams & Wilkins, 111.
  • Kowalski RP, Yates KA, Romanowski EG, Karenchak LM, Mah ES & Gordon YJ (2005): An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data. Ophthalmology 112: 19871991.
  • Krohn MA, Hillier SL, Bell TA, Kronmal RA & Grayston JT (1993): The bacterial etiology of conjunctivitis in early infancy. Am J Epidemiol 138: 326332.
  • Lærum E, Fiskaadal HJ, Erdal JE & Løberg RM (1994): Kloramfenikol øyedråper ved akutt bakteriell konjunktivitt [Chloramphenicol eyedrops in acute bacterial conjunctivitis. A comparison of 2 dosage regimes in general practice]. Tidsskr Nor Lægefor 114: 671673.
  • Lancaster T, Swart AM & Jick H (1998): Risk of serious haematolocical toxicity with use of chloramphenicol eye drops in a British general practice database. Br Med J 316: 667.
  • Leibowitz HM (1991): Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. Am J Ophthalmol 112 (Suppl): 2933.
  • Lie KK (1994): Konjunktivitt og barnehager. Statens Institutt for Folkehelse MSIS-Rapport 22:6. Oslo: Statens Institutt for Folkehelse.
  • Locatcher-Khorazo D & Seegal B (1972): Microbiology of the eye. St Louis: Mosby.
  • MacKean JM & Elkington AR (1983): Compliance with treatment of patients with chronic open-angle glaucoma. Br J Ophtalmol 67: 4649.
  • Mahajan VM (1983): Acute bacterial infections of the eye: their aetiology and treatment. Br J Ophthalmol 67: 191194.
  • Mannis MJ & Plotnik RD (2005): Bacterial conjunctivitis. In: TasmanM & JaegerEA (eds) Duane's clinical ophthalmology, vol. 4. Philadelphia: Lippincott, Williams & Wilkins, 111.
  • Martins EN, Alvarenga LS, Höfling-Lima AL, Freitas D, Zorat-Yu MC, Farah ME & Mannis MJ (2004): Aerobic bacterial conjunctival flora in diabetic patients. Cornea 23: 136142.
  • Mason BW & Howard AJ (2004): Fusidic acid resistance in community isolates of methicillin susceptible Staphylococcus aureus and the use of topical fusidic acid: a retrospective case–control study. Int J Antimicrob Agents 23: 300303.
  • McClellan KA (1997): Mucosal defence of the outer eye. Surv Ophthalmol 42: 233245.
  • McCormick M, Fleming D & Charlton J (1995): Morbidity statistics from general practice: Fourth National Survey 1991–92. London. HMSO.
  • McDonnell PJ (1988): How do general practitioners manage eye disease in the community? Br J Ophthalmol 72: 733736.
  • McMinn PC, Stewart J & Burrell CJ (1991): A community outbreak of epidemic keratoconjunctivitis in Central Australia due to adenovirus type 8. J Infect Dis 164: 11131118.
  • Midtvedt T (2004): Om bruken av antimikrobielle midler. In: VilbergA (ed.) Norsk legemiddelhåndbok for helsepersonell. Oslo: Foreningen for utgivelse av Norsk legemiddelhåndbok, 602606.
  • Miller B & Ellis P (1977): Conjunctival flora in patients receiving immunosuppressive drugs. Arch Ophthalmol 95: 20122014.
  • Miller IM, Vogel R, Cook TJ & Wittreich JM (1992a): Topically administered norfloxacin compared with topically administered gentamicin for the treatment of external ocular bacterial infections. Am J Ophthalmol 113: 638644.
  • Miller IM, Wittreich JM, Cook T & Vogel R (1992b): The safety and efficacy of topical norfloxacin compared with chloramphenicol for the treatment of external ocular bacterial infections. Eye 6: 111114.
  • Norell SE (1981): Monitoring compliance with pilocarpine therapy. Am J Ophthalmol 92: 727731.
  • Normann EK (2005): Conjunctivitis in children. Lancet 366: 67.
  • Normann EK, Bakken O, Peltola J, Andreasson B, Buhl S, Sigg P & Nielsen K (2002): Treatment of acute neonatal bacterial conjunctivitis: a comparison of fusidic acid to chloramphenicol eye drops. Acta Ophthalmol Scand 80: 183187.
  • O'Brien TP & Hahn TW (2005): Therapy of bacterial infections of the eye. In: TasmanM & JaegerEA (eds) Duane's clinical ophthalmology, vol. 3. Philadelphia: Lippincott, Williams & Wilkins, 69.
  • Olafsen LD, Størvold G & Melby K (1986): A microbiological study of conjunctivitis with emphasis on Chlamydia trachomatis in Northern Norway. Acta Ophthalmol (Copenh) 64: 463470.
  • Orden Martinez B, Martinez Ruiz R & Millan PR (2004): Conjunctivitis bacteriana: patógenos más prevalentes y sensibilidad antibiótica [Bacterial conjunctivitis: most prevalent pathogens and their antibiotic sensitivity]. An Pediatr (Barc) 61: 3236.
  • Papa V, Aragona P, Scuderi AC, Blanco AR, Di Zola PBA, Santocono M & Milazzo G (2002): Treatment of acute bacterial conjunctivitis with topical netilmicin. Cornea 21: 4347.
  • Rapoza PA, Quinn TC, Kiesling LA & Taylor HR (1986): Epidemiology of neonatal conjunctivitis. Ophthalmology 93: 456461.
  • Ravenscroft JC, Layton A & Barnham M (2000): Observations on high levels of fusidic acid resistant Staphylococcus aureus in Harrogate, North Yorkshire, UK. Clin Exp Dermatol 25: 327330.
  • Rayner SA & Buckley RJ (1996): Ocular chloramphenicol and aplastic anemia. Is there a link? Drug Safety 14: 273276.
  • Richardson M, Elliman D, Maguire H, Simpson J & Nicoll A (2001): Evidence base of incubation periods, periods of infectiousness and exclusion policies for the control of communicable diseases in schools and preschools. Pediatr Infect Dis J 20: 380391.
  • Rietveld RP, Ter Riet G, Bindels PJE, Bink D, Sloos JH & Van Weert HCPM (2005): The treatment of acute infectious conjunctivitis with fusidic acid: a randomised controlled trial. Br J General Pract 55: 924930.
  • Rietveld RP, Ter Riet G, Bindels PJE, Sloos JH & Van Weert HCPM (2004): Predicting bacterial cause in infectious conjunctivitis: cohort study on informativeness of combinations of signs and symptoms. Br Med J 329: 206210.
  • Rietveld RP, Van Wert HCMP, Ter Riet G & Bindels PJE (2003): Diagnostic impact of signs and symptoms in acute infectious conjunctivitis: systematic literature search. Br Med J 327: 789.
  • Ringvold A, Vik E & Bevanger LS (1985): Moraxella lacunata isolated from epidemic conjunctivitis among teen-aged females. Acta Ophthalmol (Copenh) 63: 427431.
  • Ritch ML, Ritterhof RJ & Hoffman RJ (1950): A fatal case of aplastic anemia following chloramphenicol therapy. Ann Intern Med 33: 14591467.
  • Rørtveit S & Rørtveit G (2003): Epidemi av bulløs impetigo i Austevoll kommune år 2002 [An epidemic of bullous impetigo in the municipality of Austevoll in the year of 2002]. Tidsskr Nor Lægeforen 123: 25572560.
  • Rose PW, Harnden A, Brueggemann AB, Perera R, Sheikh A, Crook D & Mant D (2005): Chloramphenicol treatment for acute infective conjunctivitis in children in primary care: a randomised double-blind placebo-controlled study. Lancet 366: 3743.
  • Rosenthal RL & Blackman A (1965): Bone marrow hypoplasia following use of chloramphenicol eye drops. JAMA 191: 148149.
  • Rotchford AP & Murphy KM (1998): Compliance with timolol treatment in glaucoma. Eye 12: 234236.
  • Ruben FL, Norden CW, Heisler B & Korica Y (1984): An outbreak of Streptococcus pyogenes infections in a nursing home. Ann Intern Med 101: 494496.
  • Rubenstein JB (1999): Disorders of the conjunctiva and limbus. In: YanoffM & DukerJS (eds) Ophthalmology. St Louis: Mosby, 1218.
  • Schiebel NEE (2003): Use of antibiotics in patients with acute bacterial conjunctivitis. Ann Emerg Med 41: 407409.
  • Schmitz H, Wigand R & Heinrich W (1983): Worldwide epidemiology of human adenovirus infections. Am KJ Epidemiol 117: 455466.
  • Schwab IR, Friedlaender M, McCulley J, Lichtenstein SJ & Moran CT (2003): A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Ophthalmology 110: 457465.
  • Schwartz B, Harrison LH, Motter JS, Motter RN, Hightower AW & Broome CV (1989): Investigation of an outbreak of Moraxella conjunctivitis at a Navajo boarding school. Am J Ophthalmol 107: 341347.
  • Seibel W & Ruprecht KW (1983): Bacteriologische Befunde in Bindehautabstrichen [Bacteriological findings in conjunctival smears]. Klin Mbl Augenheilk 183: 6062.
  • Shah M & Mohanraj M (2003): High levels of fusidic acid-resistant Staphylococcus aureus in dermatology patients. Br J Dermatol 148: 10181020.
  • Sharma T, Grewal J, Gupta S & Murray PI (2004): Ophthalmic manifestations of acute leucemias: the ophthalmologist's role. Eye 18: 663672.
  • Shayegani M, Parsons LM, Gibbons WE Jr & Cambell D (1982): Characterization of nontypable Streptococcus pneumoniae-like organisms isolated from outbreaks of conjunctivitis. J Clin Microbiol 16: 814.
  • Sheikh A & Hurwitz B (2001): Topical antibiotics for acute bacterial conjunctivitis: a systematic review. Br J General Prac 51: 473477.
  • Sheikh A & Hurwitz B (2005): Topical antibiotics for acute bacterial conjunctivitis: Cochrane systematic review and meta-analysis update. Br J General Prac 55: 962964.
  • Sheikh A & Hurwitz B (2006): Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev 2: CD001211.
  • Singer TR, Isenberg SJ & Apt L (1988): Conjunctival anaerobic and aerobic bacterial flora in paediatric versus adult subjects. Br J Ophthalmol 72: 448451.
  • Solberg R, Meberg A & Schøyen R (1991): Neonatal konjunktivitt i en barselavdeling og en neonatalenhet [Neonatal conjunctivitis in a nursery and a neonatal unit]. Tidsskr Nor Lægefor 111: 12301232.
  • Starr MB (2004): How best to treat adenoviral corneal opacities? Cornea 23: 217219.
  • Stern GA & Killingsworth DW (1989): Complications of topical antimicrobial agents. Int Ophthalmol Clin 29: 137142.
  • Tarabishy AB, Hall GS, Procop GW & Jeng BH (2006): Bacterial culture isolates from hospitalized pediatric patients with conjunctivitis. Am J Ophthalmol 142: 678680.
  • Thiel HJ & Schumacher U (1994): Über die Standortflora der menschlichen Bindehaut. Untersuchungen von 135 Personen unterschiedlichen Alters [Normal flora of the human conjunctiva: a study of 135 persons of various ages]. Klin Monatbl Augenheilk 205: 348357.
  • Thorn P & Johansen S (1997): Pharmacokinetic investigation of fusidic acid 1% viscous eye drops in healthy volunteers. Eur J Ophthalmol 7: 912.
  • Trottier S, Stenberg K, Von Rosen IA & Svanborg C (1991): Haemophilus influenzae causing conjunctivitis in day-care children. Pediatr Infect Dis J 10: 578584.
  • Wald ER, Greenberg D & Hoberman A (2001): Short term oral cefixime therapy for treatment of bacterial conjunctivitis. Pediatr Infect Dis J 21: 10391042.
  • Walker S, Diaper CJM, Bowman R, Sweeney G, Seal DV & Kirkness CM (1998): Lack of evidence for systemic toxicity following topical chloramphenicol use. Eye 12: 875879.
  • Wall AR, Sinclair N & Adenis JP (1998): Comparison of Fucithalmic® (fusidic acid viscous eye drops 1%) and Noroxin (norfloxacin ophthalmic solution 0.3%) in the treatment of acute bacterial conjunctivitis. J Drug Assess 1: 549558.
  • Wallerstein RO, Condit PK, Kasper CK, Brown JW & Morrison FR (1969): Statewide study of chloramphenicol therapy and fatal aplastic anemia. JAMA 208: 20452050.
  • Weiss A, Brinser JH & Nazar-Stewart V (1993): Acute conjunctivitis in childhood. J Pediatr 122: 1014.
  • Wiholm B-E, Kelly JP, Kaufman D, Issaragrisil S, Levy M, Anderson T & Shapiro S (1998): Relation of aplastic anaemia to use of chloramphenicol eye drops in two international case–control studies. Br Med J 328: 666.
  • Wilhelmus KR (2005): Epidemiology of ocular infections. In: TasmanM & JaegerEA (eds) Duane's clinical ophthalmology, vol. 2. Town: Lippincott, Williams & Wilkins, 164.
  • Yamauchi Y, Minoda H, Yokoi K, Maruyama K, Kumakura S, Usui M, Cruz JM & Fukutake K (2005): Conjunctival flora in patients with human immunodeficiency virus infection. Ocul Immunol Inflamm 13: 301304.
  • Yee RW, Tepedino M, Bernstein P, Jensen H, Schiffmann R & Whitcup SM (2005): A randimized, investigator-masked clinical trial comparing the efficacy and safety of gatifloxacin 0.3% administered BID versus QID for the treatment of acute bacterial conjunctivitis. Curr Med Res Opin 21: 425431.
  • Yunis A (1973): Chloramphenicol induced bone marrow suppression. Semin Hematol 10: 225234.
  • Zinn CS, Westh H & Rosdahl VT (2004): An international multicenter study of antimicrobial resistance and typing of hospital Staphylococcus aureus isolates from 21 laboratories in 19 countries or states. Microb Drug Resist 10: 160168.